Durvalumab (MEDI4736) with Chemotherapy as First Line Treatment in Advanced Pleural Mesothelioma

Brief description of study

Patients with malignant pleural mesothelioma (MPM) that cannot be surgically removed will receive first-line treatment with standard chemotherapy of cisplatin or carboplatin and pemetrexed. T Durvalumab is an antibody (a type of human protein) that works by blocking a body substance called Programmed Death-Ligand 1 (PD-L1). Blocking PD-L1 helps the body's immune system attack cancer cells. Research has shown that durvalumab can slow tumor growth and shrink tumors in some people with cancer. Previous studies of combining durvalumab and chemotherapy showed that this combination is active in advanced mesothelioma. The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS) in patients with MPM.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Advanced Pleural Mesothelioma,Mesothelioma,Malignant Pleural Mesothelioma
Age: Between 18 Years - 99 Years
Gender: All

Male or Female, Age 18 or older, with histological diagnosis of malignant pleural mesothelioma

Updated on 09 Mar 2024. Study ID: 844949

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).